Abstract
It has been suggested that inflammation is important in the aetiology of hypertension and that this may be most relevant among obese persons. To study this, we examined the independent relationships between obesity, inflammation-related proteins (interleukin-6 (IL-6), C-reactive protein (CRP) and fibrinogen) and risk for hypertension in the Multi-Ethnic Study of Atherosclerosis (MESA). Hypertension status, defined as a blood pressure ⩾140/90 mm Hg or a history of hypertension and use of blood pressure medications, was determined at baseline and two subsequent exams over 5 years. Among 3543 non-hypertensives at baseline, 714 individuals developed incident hypertension by Exam 3. Cox proportional hazard models were used to determine the relationship between baseline levels of IL-6, CRP and fibrinogen and future risk of hypertension. One s.d. difference in baseline concentration of IL-6, CRP or fibrinogen was associated with 20–40% greater risk of incident hypertension. This risk was attenuated after accounting for other hypertension risk factors (hazard ratio (HR) IL-6: 1.13 (95% CI: 1.04–1.23); CRP: 1.11 (95% CI: 1.02–1.21); fibrinogen 1.0 (95% CI: 0.92–1.08)). Conversely, obesity was an independent risk factor for hypertension risk, minimally impacted by other covariates, including IL-6 and CRP (HR 1.72 (95% CI: 1.36–2.16)). IL-6 and CRP did not modify the relationship between obesity and hypertension, though an adjusted twofold greater risk was observed for obese individuals with a CRP >3 mg l−1 compared with CRP <1 mg l−1. The relationship between inflammation-related proteins and hypertension risk was predominantly explained by other hypertension risk factors. Obesity, independent of inflammation, remained a potent risk factor for future hypertension.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Niskanen L, Laaksonen DE, Nyyssonen K, Punnonen K, Valkonen VP, Fuentes R et al. Inflammation, abdominal obesity, and smoking as predictors of hypertension. Hypertension 2004; 44 (6): 859–865.
Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM . C-reactive protein and the risk of developing hypertension. JAMA 2003; 290 (22): 2945–2951.
Blake GJ, Rifai N, Buring JE, Ridker PM . Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation 2003; 108 (24): 2993–2999.
Cassano PA, Segal MR, Vokonas PS, Weiss ST . Body fat distribution, blood pressure, and hypertension. A prospective cohort study of men in the normative aging study. Ann Epidemiol 1990; 1 (1): 33–48.
Garrison RJ, Kannel WB, Stokes III J, Castelli WP . Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med 1987; 16 (2): 235–251.
Huang Z, Willett WC, Manson JE, Rosner B, Stampfer MJ, Speizer FE et al. Body weight, weight change, and risk for hypertension in women. Ann Intern Med 1998; 128 (2): 81–88.
Gelber RP, Gaziano JM, Manson JE, Buring JE, Sesso HD . A prospective study of body mass index and the risk of developing hypertension in men. Am J Hypertens 2007; 20 (4): 370–377.
Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB . Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999; 282 (22): 2131–2135.
Greenberg AS, Obin MS . Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr 2006; 83 (2): 461S–465S.
Wee CC, Mukamal KJ, Huang A, Davis RB, McCarthy EP, Mittleman MA . Obesity and C-reactive protein levels among white, black, and hispanic US adults. Obesity (Silver Spring) 2008; 16 (4): 875–880.
Lakoski SG, Herrington DM, Siscovick DM, Hulley SB . C-reactive protein concentration and incident hypertension in young adults: the CARDIA study. Arch Intern Med 2006; 166 (3): 345–349.
Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR et al. Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol 2002; 156 (9): 871–881.
Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26 (11): 3160–3167.
Friedewald WT, Levy RI, Fredrickson DS . Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18 (6): 499–502.
Lakoski SG, Cushman M, Palmas W, Blumenthal R, D’Agostino Jr RB, Herrington DM . The relationship between blood pressure and C-reactive protein in the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol 2005; 46 (10): 1869–1874.
Sesso HD, Wang L, Buring JE, Ridker PM, Gaziano JM . Comparison of interleukin-6 and C-reactive protein for the risk of developing hypertension in women. Hypertension 2007; 49 (2): 304–310.
Bautista LE, Vera LM, Arenas IA, Gamarra G . Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens 2005; 19 (2): 149–154.
Folsom AR, Peacock JM, Nieto FJ, Rosamond WD, Eigenbrodt ML, Davis CE et al. Plasma fibrinogen and incident hypertension in the Atherosclerosis Risk in Communities (ARIC) Study. J Hypertens 1998; 16 (11): 1579–1583.
Shankar A, Wang JJ, Rochtchina E, Mitchell P . Positive association between plasma fibrinogen level and incident hypertension among men: population-based cohort study. Hypertension 2006; 48 (6): 1043–1049.
Engeli S, Negrel R, Sharma AM . Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000; 35 (6): 1270–1277.
Brasier AR, Recinos III A, Eledrisi MS . Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002; 22 (8): 1257–1266.
Yudkin JS . Adipose tissue, insulin action and vascular disease: inflammatory signals. Int J Obes Relat Metab Disord 2003; 27 (Suppl 3): S25–S28.
Kaplan NM . Kaplan's Clinical Hypertension, 8th edn. Lippincott Williams & Williams: Philadelphia, 2002.
Rahmouni K, Correia ML, Haynes WG, Mark AL . Obesity-associated hypertension: new insights into mechanisms. Hypertension 2005; 45 (1): 9–14.
Reaven GM, Lithell H, Landsberg L . Hypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334 (6): 374–381.
Landsberg L . Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J Med 1986; 61 (236): 1081–1090.
Tuck ML . Obesity, the sympathetic nervous system, and essential hypertension. Hypertension 1992; 19 (1 Suppl): I67–I77.
Acknowledgements
We thank the other investigators, the staff and the participants of the MESA study for their valuable contributions. A full list of participating MESA investigators and institutions can be found at http://www.mesa-nhlbi.org. Source of Funding: This research was supported by contracts N01-HC-95159 through N01-HC-95166 and Grant NHLBI T32 HL076132-01 from the National Heart, Lung and Blood Institute.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Lakoski, S., Cushman, M., Siscovick, D. et al. The relationship between inflammation, obesity and risk for hypertension in the Multi-Ethnic Study of Atherosclerosis (MESA). J Hum Hypertens 25, 73–79 (2011). https://doi.org/10.1038/jhh.2010.91
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/jhh.2010.91
Keywords
This article is cited by
-
Very low-calorie ketogenic diet (VLCKD): an antihypertensive nutritional approach
Journal of Translational Medicine (2023)
-
The relationship between serum C-reactive protein and senile hypertension
BMC Cardiovascular Disorders (2022)
-
Countering adipose tissue dysfunction could underlie the superiority of telmisartan in the treatment of obesity-related hypertension
Cardiovascular Diabetology (2021)
-
Inflammation and hypertension: more evidence but is there anything new?
Journal of Human Hypertension (2021)
-
Role of metformin in overweight and obese people without diabetes: a systematic review and network meta-analysis
European Journal of Clinical Pharmacology (2019)